ISA Pharmaceuticals appoints Gerard Platenburg as CEO

April 21, 2009

ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management team.

Gerard Platenburg has been appointed as the new Chief Executive Officer becoming responsible for the overall management and strategic direction of the company. He brings to ISA Pharmaceuticals over 20 years of corporate experience in the biotech industry.

Mr. Platenburg previously founded and developed Prosensa into a clinical stage company, with a focus on therapy development for neuromuscular disorders. Mr. Platenburg commented, "I look forward to working with the highly professional and talented team at ISA. It is a privilege to contribute to the mission of developing therapies based on ISA's SLPĀ® technology, providing hope to patients and their families."

"Gerard has a vast experience that will proof to be very valuable to ISA. With his strong history as a results driven leader, I am confident that he will take ISA to the next level as a leading company in the field of therapeutic vaccines", said Mark Krul, Chairman of the Board.

Home > News & Events > ISA Pharmaceuticals appoints Gerard Platenburg...

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds